研究発表等（講演・口頭発表等） - 織内 昇
-
Expression of Glucose Transporter in hepatocellular carcinoma compared with FDG-PET
65th annual meeting of Japanese Radiological Society,
-
Design and management of PET facility (PET scanner, hot laboratory and clinical cyclotron)
IAEA-RCA Regional Training Course on “PET Applications for Oncologists, Radiation Oncologists and Haematologists” for RAS/6/042 2006.
-
Diagnosis of primary tumor in patients with cancer of unknown primary using F-18-FDG PET.
European Association of Nuclear Medicine Congress.
-
Preclinical evaluation of 67Cu-labeled monoclonal antibody for cancer therapy.
53th Annual Meeting of the Society of Nuclear Medicine
-
Clinical study using L-3-[18F] fluoro-methyltyrosine (FAMT) and 18F-FDG PET for maxillofacial tumor: Comparative immunohistopathological analysis with cellular proliferation (Ki-67) and amino-acid transporter expression (LAT-1).
53th Annual Meeting of the Society of Nuclear Medicine
-
Usefulness of FDG-PET for the evaluation of maxillofacial tumors: Comparison to conventional studies with CT/MRI.
53th Annual Meeting of the Society of Nuclear Medicine
-
Diagnosis of carcinoma of unknown primary with F-18-FDG PET.
9th Congress of World Federation of Nuclear Medicine & Biology
-
Expression of Glucose Transporter in hepatocellular carcinoma compared with FDG-PET
65th annual meeting of Japanese Radiological Society,
-
Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody, NuB2, for cancer therapy.
52th Annual Meeting of the Society of Nuclear Medicine
-
Correlation between FDG-PET and alpha fetoprotein in the evaluation of recurrent hepatocellular carcinoma treated with radiofrequency ablation
45th Annual meeting of Japanese society of Nuclear medicine (JSNM )
-
Cellular proliferation and amino-acid transporter expression of maxillofacial tumor evaluated with L-3-[18F]fluoro-alpha-methyltyrosine (FAMT) and 18F-FDG PET.
Australian and New Zealand Society of Nuclear Medicine 35th Annual Scientific Meeting 2005
-
Use of FDG-PET in the evaluation of recurrent hepatocellular carcinoma treated with radiofrequency ablation.
Australian and New Zealand Society of Nuclear Medicine 35th Annual Scientific Meeting 2005
-
Preclinical Evaluation of Radiolabeled Anti-CD20 Monoclonal Antibody, NuB2, for Cancer Therapy.
EANM'05 - Annual Congress of the European Assocation of Nuclear Medicine
-
A preliminary of the usefulness of L-3-[18F]fluoro-alpha-methyltyrosine (FAMT) PET in the evaluation of malignancy of maxillofacial tumor; Comparative study with 18F-FDG PET and immunohistochemical analysis of cellular proliferation (Ki-67) and amino-a・・・
EANM'05 - Annual Congress of the European Assocation of Nuclear Medicine
-
Clinical study using L-3-[18F]fluoro-alpha-methyltyrosine (FAMT) and 18F-FDG PET for maxillofacial tumor with analysis on cellular proliferation (Ki-67) and amino-acid transporter expression (LAT-1).
The Second International Symposium on Biomedical Research Using Accelerator Technology
-
悪性褐色細胞腫のI-131 MIBG治療中にFDG-PETで見られる褐色脂肪組織への集積とノルアドレナリン刺激との関係．
第64回日本癌学会総会
-
ヒト型モノクローナル抗体huA33を用いた胃癌治療のPhase I 臨床研究
第64回日本癌学会
-
Cellular proliferation and amino-acid transporter expression of maxillofacial tumor evaluated with L-3[18F]fluoro-alpha-methyltyrosine and 18F-FDG PET.
The First International Symposium on Biomedical Research Using Accelerator Technology
-
放射性同位元素のがん治療への応用．
第64回日本医学放射線学会総会
-
悪性褐色細胞腫のI-131 MIBG治療中にFDG-PETで見られる褐色脂肪組織への集積とノルアドレナリン刺激との関係．
第64回日本医学放射線学会総会